Switch to:
Also traded in: Argentina, Germany, Mexico, Sweden, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.46
AZN's Cash to Debt is ranked lower than
67% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.63 vs. AZN: 0.46 )
Ranked among companies with meaningful Cash to Debt only.
AZN' s Cash to Debt Range Over the Past 10 Years
Min: 0.2  Med: 2.97 Max: N/A
Current: 0.46
Equity to Asset 0.31
AZN's Equity to Asset is ranked lower than
87% of the 677 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. AZN: 0.31 )
Ranked among companies with meaningful Equity to Asset only.
AZN' s Equity to Asset Range Over the Past 10 Years
Min: 0.3  Med: 0.46 Max: 0.59
Current: 0.31
0.3
0.59
Interest Coverage 3.83
AZN's Interest Coverage is ranked lower than
86% of the 470 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 123.58 vs. AZN: 3.83 )
Ranked among companies with meaningful Interest Coverage only.
AZN' s Interest Coverage Range Over the Past 10 Years
Min: 5.58  Med: 11.05 Max: 15.02
Current: 3.83
5.58
15.02
F-Score: 5
Z-Score: 2.16
M-Score: -2.74
WACC vs ROIC
7.39%
15.61%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 16.65
AZN's Operating margin (%) is ranked higher than
74% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.82 vs. AZN: 16.65 )
Ranked among companies with meaningful Operating margin (%) only.
AZN' s Operating margin (%) Range Over the Past 10 Years
Min: 8.19  Med: 29.04 Max: 38.09
Current: 16.65
8.19
38.09
Net-margin (%) 11.43
AZN's Net-margin (%) is ranked higher than
68% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.45 vs. AZN: 11.43 )
Ranked among companies with meaningful Net-margin (%) only.
AZN' s Net-margin (%) Range Over the Past 10 Years
Min: 4.73  Med: 20.98 Max: 29.72
Current: 11.43
4.73
29.72
ROE (%) 15.67
AZN's ROE (%) is ranked higher than
74% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. AZN: 15.67 )
Ranked among companies with meaningful ROE (%) only.
AZN' s ROE (%) Range Over the Past 10 Years
Min: 5.89  Med: 37.06 Max: 45.52
Current: 15.67
5.89
45.52
ROA (%) 5.04
AZN's ROA (%) is ranked higher than
56% of the 740 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.67 vs. AZN: 5.04 )
Ranked among companies with meaningful ROA (%) only.
AZN' s ROA (%) Range Over the Past 10 Years
Min: 2.2  Med: 14.51 Max: 20.88
Current: 5.04
2.2
20.88
ROC (Joel Greenblatt) (%) 67.93
AZN's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.76 vs. AZN: 67.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AZN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 28.15  Med: 120.23 Max: 199.48
Current: 67.93
28.15
199.48
Revenue Growth (3Y)(%) -5.70
AZN's Revenue Growth (3Y)(%) is ranked lower than
81% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. AZN: -5.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AZN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -42.9  Med: 4.85 Max: 20
Current: -5.7
-42.9
20
EBITDA Growth (3Y)(%) -30.70
AZN's EBITDA Growth (3Y)(%) is ranked lower than
88% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. AZN: -30.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AZN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -38.9  Med: 9.35 Max: 24.7
Current: -30.7
-38.9
24.7
EPS Growth (3Y)(%) -48.90
AZN's EPS Growth (3Y)(%) is ranked lower than
94% of the 487 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. AZN: -48.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AZN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -48.9  Med: 11.40 Max: 24.7
Current: -48.9
-48.9
24.7
» AZN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

AZN Guru Trades in Q1 2015

Jim Simons 3,154,400 sh (+37.87%)
Pioneer Investments 758,498 sh (+0.55%)
Manning & Napier Advisors, Inc 227,870 sh (unchged)
Murray Stahl 13,000 sh (unchged)
Francis Chou 13,000 sh (unchged)
David Dreman 27,489 sh (-4.43%)
NWQ Managers 52,265 sh (-21.34%)
Mario Gabelli 11,800 sh (-40.70%)
John Hussman 52,000 sh (-70.03%)
Steven Cohen 61,800 sh (-89.48%)
» More
Q2 2015

AZN Guru Trades in Q2 2015

NWQ Managers 153,255 sh (+486.45%)
Murray Stahl 26,000 sh (+300.00%)
Jim Simons 3,934,600 sh (+149.47%)
Pioneer Investments 759,059 sh (+100.15%)
John Hussman 42,000 sh (+61.54%)
Manning & Napier Advisors, Inc 227,870 sh (unchged)
Steven Cohen 50,200 sh (unchged)
Francis Chou 13,000 sh (unchged)
David Dreman Sold Out
Steven Cohen Sold Out
Mario Gabelli 4,200 sh (-28.81%)
» More
Q3 2015

AZN Guru Trades in Q3 2015

Ken Fisher 27,947 sh (New)
PRIMECAP Management 183,900 sh (New)
NWQ Managers 490,535 sh (+60.04%)
Pioneer Investments 1,522,676 sh (+0.30%)
Manning & Napier Advisors, Inc 455,740 sh (unchged)
Francis Chou 26,000 sh (unchged)
Manning & Napier Advisors, Inc 227,870 sh (unchged)
Mario Gabelli Sold Out
Jim Simons 5,452,900 sh (-30.71%)
Murray Stahl 28,000 sh (-46.15%)
John Hussman 2,000 sh (-97.62%)
» More
Q4 2015

AZN Guru Trades in Q4 2015

Ken Fisher 221,606 sh (+692.95%)
John Hussman 2,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AZN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about AstraZeneca PLC

Francis Chou Doubles Stake in AstraZeneca
Francis Chou (Trades, Portfolio) of Chou Associates Management runs a concentrated portfolio of just 22 stocks, trading in only two of them during the second quarter. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 46.90
AZN's P/E(ttm) is ranked lower than
70% of the 499 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.00 vs. AZN: 46.90 )
Ranked among companies with meaningful P/E(ttm) only.
AZN' s P/E(ttm) Range Over the Past 10 Years
Min: 6.04  Med: 12.25 Max: 99.47
Current: 46.9
6.04
99.47
Forward P/E 13.44
AZN's Forward P/E is ranked higher than
72% of the 236 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.62 vs. AZN: 13.44 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 46.80
AZN's PE(NRI) is ranked lower than
70% of the 496 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.20 vs. AZN: 46.80 )
Ranked among companies with meaningful PE(NRI) only.
AZN' s PE(NRI) Range Over the Past 10 Years
Min: 6.02  Med: 12.26 Max: 99.72
Current: 46.8
6.02
99.72
P/B 4.21
AZN's P/B is ranked lower than
67% of the 706 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.79 vs. AZN: 4.21 )
Ranked among companies with meaningful P/B only.
AZN' s P/B Range Over the Past 10 Years
Min: 2.3  Med: 3.78 Max: 6.97
Current: 4.21
2.3
6.97
P/S 4.34
AZN's P/S is ranked lower than
66% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.72 vs. AZN: 4.34 )
Ranked among companies with meaningful P/S only.
AZN' s P/S Range Over the Past 10 Years
Min: 2.26  Med: 3.27 Max: 5.21
Current: 4.34
2.26
5.21
PFCF 44.67
AZN's PFCF is ranked lower than
59% of the 248 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. AZN: 44.67 )
Ranked among companies with meaningful PFCF only.
AZN' s PFCF Range Over the Past 10 Years
Min: 6.18  Med: 13.38 Max: 50.18
Current: 44.67
6.18
50.18
POCF 17.56
AZN's POCF is ranked higher than
66% of the 384 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.79 vs. AZN: 17.56 )
Ranked among companies with meaningful POCF only.
AZN' s POCF Range Over the Past 10 Years
Min: 5.35  Med: 8.60 Max: 19.73
Current: 17.56
5.35
19.73
EV-to-EBIT 28.12
AZN's EV-to-EBIT is ranked lower than
64% of the 515 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.63 vs. AZN: 28.12 )
Ranked among companies with meaningful EV-to-EBIT only.
AZN' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.3  Med: 11.10 Max: 41.5
Current: 28.12
5.3
41.5
EV-to-EBITDA 16.53
AZN's EV-to-EBITDA is ranked higher than
53% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.42 vs. AZN: 16.53 )
Ranked among companies with meaningful EV-to-EBITDA only.
AZN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.6  Med: 9.20 Max: 21.8
Current: 16.53
4.6
21.8
Shiller P/E 15.58
AZN's Shiller P/E is ranked higher than
86% of the 140 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.61 vs. AZN: 15.58 )
Ranked among companies with meaningful Shiller P/E only.
AZN' s Shiller P/E Range Over the Past 10 Years
Min: 10.09  Med: 15.65 Max: 26.75
Current: 15.58
10.09
26.75
Current Ratio 0.82
AZN's Current Ratio is ranked lower than
93% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.27 vs. AZN: 0.82 )
Ranked among companies with meaningful Current Ratio only.
AZN' s Current Ratio Range Over the Past 10 Years
Min: 0.64  Med: 1.50 Max: 2.03
Current: 0.82
0.64
2.03
Quick Ratio 0.69
AZN's Quick Ratio is ranked lower than
87% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.65 vs. AZN: 0.69 )
Ranked among companies with meaningful Quick Ratio only.
AZN' s Quick Ratio Range Over the Past 10 Years
Min: 0.54  Med: 1.28 Max: 2.03
Current: 0.69
0.54
2.03
Days Inventory 163.19
AZN's Days Inventory is ranked lower than
69% of the 643 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 118.46 vs. AZN: 163.19 )
Ranked among companies with meaningful Days Inventory only.
AZN' s Days Inventory Range Over the Past 10 Years
Min: 88.45  Med: 122.07 Max: 168.19
Current: 163.19
88.45
168.19
Days Sales Outstanding 105.15
AZN's Days Sales Outstanding is ranked lower than
70% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.01 vs. AZN: 105.15 )
Ranked among companies with meaningful Days Sales Outstanding only.
AZN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 59.12  Med: 73.57 Max: 95.12
Current: 105.15
59.12
95.12

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.66
AZN's Dividend Yield is ranked higher than
91% of the 688 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.45 vs. AZN: 4.66 )
Ranked among companies with meaningful Dividend Yield only.
AZN' s Dividend Yield Range Over the Past 10 Years
Min: 1.94  Med: 4.45 Max: 7.64
Current: 4.66
1.94
7.64
Dividend Payout 2.09
AZN's Dividend Payout is ranked lower than
73% of the 419 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. AZN: 2.09 )
Ranked among companies with meaningful Dividend Payout only.
AZN' s Dividend Payout Range Over the Past 10 Years
Min: 0.23  Med: 0.91 Max: 4.87
Current: 2.09
0.23
4.87
Dividend Growth (3y) -2.00
AZN's Dividend Growth (3y) is ranked lower than
63% of the 280 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. AZN: -2.00 )
Ranked among companies with meaningful Dividend Growth (3y) only.
AZN' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -4.5  Med: 11.60 Max: 28.3
Current: -2
-4.5
28.3
Forward Dividend Yield 3.00
AZN's Forward Dividend Yield is ranked higher than
97% of the 610 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. AZN: 3.00 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 6.32
AZN's Yield on cost (5-Year) is ranked higher than
91% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.86 vs. AZN: 6.32 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
AZN' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.63  Med: 6.04 Max: 10.37
Current: 6.32
2.63
10.37
3-Year Average Share Buyback Ratio 2.60
AZN's 3-Year Average Share Buyback Ratio is ranked higher than
96% of the 462 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.90 vs. AZN: 2.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AZN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -123.9  Med: 2.15 Max: 4.6
Current: 2.6
-123.9
4.6

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.29
AZN's Price/Projected FCF is ranked higher than
80% of the 313 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.72 vs. AZN: 1.29 )
Ranked among companies with meaningful Price/Projected FCF only.
AZN' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.7  Med: 1.40 Max: 5.98
Current: 1.29
0.7
5.98
Price/Median PS Value 1.33
AZN's Price/Median PS Value is ranked lower than
60% of the 612 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.18 vs. AZN: 1.33 )
Ranked among companies with meaningful Price/Median PS Value only.
AZN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.38  Med: 1.23 Max: 2.16
Current: 1.33
0.38
2.16
Earnings Yield (Greenblatt) (%) 3.60
AZN's Earnings Yield (Greenblatt) (%) is ranked higher than
56% of the 723 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. AZN: 3.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AZN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.4  Med: 9.00 Max: 18.8
Current: 3.6
2.4
18.8
Forward Rate of Return (Yacktman) (%) -11.72
AZN's Forward Rate of Return (Yacktman) (%) is ranked lower than
82% of the 325 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.77 vs. AZN: -11.72 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AZN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -14  Med: 18.40 Max: 28
Current: -11.72
-14
28

More Statistics

Revenue(Mil) $24708
EPS $ 1.11
Beta0.72
Short Percentage of Float0.40%
52-Week Range $29.50 - 36.69
Shares Outstanding(Mil)2528.00

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 23,719 24,703 24,467
EPS($) 1.87 2.23 2.38
EPS without NRI($) 1.87 2.23 2.38

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:AZN.Argentina, ZEG.Germany, AZNN.Mexico, AZN.Sweden, OXAZN.Switzerland, AZN.UK, AZNCF.USA,
AstraZeneca PLC was incorporated in England and Wales on June 17, 1992. From February 1993 until April 1999, the Company was called Zeneca Group PLC. On 6 April 1999, the Company changed its name to AstraZeneca PLC. It is a biopharmaceutical company. The Company is engaged in the discovery and development of new products, which are then manufactured, marketed and sold. It is engaged in healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). The Company is also engaged in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. It operates in more than 100 countries.
» More Articles for AZN

Headlines

Articles On GuruFocus.com
Signature Select Canadian Fund Second Quarter 2015 Market Commentary Sep 22 2015 
Francis Chou Doubles Stake in AstraZeneca Aug 11 2015 
Last Month Insiders Bought Over $300 Million Of This Biotech Jun 26 2015 
Guru Stocks at 52-Week Lows: XOM, WMT, CVX, AZN, COP Jun 21 2015 
Amgen And AstraZeneca’s Deal On Psoriasis Drug Faces Termination May 27 2015 
Johnson & Johnson A Good Investment Despite Current Lows May 14 2015 
Vanguard Adds to Four of Its Largest Stakes May 04 2015 
HealthCare Stocks That Can Make Investors Healthier Apr 08 2015 
Regulus Therapeutics (RGLS) microRNA Therapeutic Milestone Payment, Dave & Buster's Entertainment (P Apr 08 2015 
Pfizer Stocks Has A Lot Of Steam To Take The Investors Higher Jan 20 2015 

More From Other Websites
3:41 am AstraZeneca announces peer journal publication of early results support combination strategy... Feb 08 2016
[$$] AstraZeneca cancer drug presents breakthrough Feb 07 2016
AstraZeneca Tops Q4 Earnings, Falls on Bleak 2016 Outlook Feb 05 2016
Can AstraZeneca plc, Prudential plc & Rolls-Royce Holding PLC Escape Their Month Of Misery? Feb 05 2016
Can AstraZeneca plc, Prudential plc & Rolls-Royce Holding PLC Escape Their Month Of Misery? Feb 05 2016
Friday newspaper share tips: AstraZeneca at least worth holding on to Feb 05 2016
Questor share tip: AstraZeneca faces Crestor crunch in year ahead Feb 05 2016
Allstate and CBS are big market movers Feb 04 2016
Europe close: Shares rise as oil strengthens and US dollar weakens Feb 04 2016
Britain's FTSE 100 gets boost after weak dollar helps commodities Feb 04 2016
Weak dollar pummels European markets Feb 04 2016
AstraZeneca warns of lower profits as generic competition grows Feb 04 2016
Britain's FTSE 100 gets boost after weak dollar helps commodities Feb 04 2016
Here’s Why AstraZeneca (AZN) Stock is Dropping Today Feb 04 2016
Results round-up Feb 04 2016
AstraZeneca CEO open for deals that pay from day one Feb 04 2016
[$$] AstraZeneca Shares Slip After Earnings Warning Feb 04 2016
AstraZeneca Falls More Than 5% Following Q4 Print Feb 04 2016
AstraZeneca CEO Raises Bar for Deals After Acquisitions Spree Feb 04 2016
Britain's FTSE 100 gets boost after weak dollar helps commodities Feb 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK